![]() | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C11H15Cl2NO2 |
| Molar mass | 264.15 g·mol−1 |
| 3D model (JSmol) | |
| |
DODC is a psychedelic drug from the substituted amphetamine family which acts as an agonist of the 5-HT2A receptor. It is the 3,4-dichloro derivative of the well known psychedelic drug 2,5-Dimethoxy-4-chloroamphetamine (DOC). DODC was first officially published in a patent filed by Gilgamesh Pharmaceuticals in 2020,[1] though anecdotal reports suggest it had been synthesised by clandestine chemists and its activity established several years prior to this.
See also
References
- ↑ WO 2022/006186, Kruegel AC, "Phenalkylamines and Methods of Treating Mood Disorders.", published January 2022, assigned to Gilgamesh Pharmaceuticals.
| Phenethylamines |
|
|---|---|
| Amphetamines |
|
| Phentermines |
|
| Cathinones |
|
| Phenylisobutylamines | |
| Phenylalkylpyrrolidines | |
| Catecholamines (and close relatives) |
|
| Miscellaneous |
|
| Psychedelics (5-HT2A agonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dissociatives (NMDAR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Deliriants (mAChR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.
